The Global TransthyretinAmyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran(ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (HereditaryTransthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and WildType), and by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies,Retail Pharmacies, and Online Pharmacies) and by Geography (North America,Latin America, Europe, Asia-Pacific, Middle East and Africa) is expected to bevalued at US$ 35.8 million in 2018 and is projected to exhibit a CAGR of 55.4%over the forecast period (2018–2026).
Launch of novel therapiesindicated for the treatment of transthyretin amyloidosis is expected to propelgrowth of the market. For instance, in October 2018, Alnylam Pharmaceuticals,Inc. launched ONPATTRO (patisiran) in Germany. The drug is indicated for thetreatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adultswith stage 1 or stage 2 polyneuropathy. In October 2018, Ionis Pharmaceuticals,Inc. and Akcea Therapeutics, Inc. received the U.S. Food and DrugAdministration (FDA) approval for its novel drug TEGSEDI (inotersen) indicatedfor the treatment of polyneuropathy of hereditary transthyretin-mediatedamyloidosis in adults.
Key manufacturers in market havetheir novel therapies under development pipeline and are expected to gain approvalin the near future. Presence of robust pipeline is also expected to be one themajor factors driving the market growth. For instance, in March 2018, Pfizer,Inc. reported positive results from Phase 3 ATTR-ACT study of Tafamidis amongpatients suffering from transthyretin cardiomyopathy
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/687
Browse 35 Market Data Tables and43 Figures spread through 221 Pages and in-depth TOC on Global TransthyretinAmyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran(ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (HereditaryTransthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and WildType), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, andOnline Pharmacies) - Forecast to 2026
Key players in the market arefocused on strategic mergers and partnerships in order to enhance their marketshare. For instance, In October 2018, Ionis Pharmaceuticals, Inc. and AkceaTherapeutics, Inc. entered into distribution agreement with Accredo specialtypharmacy, a subsidiary of Express Scripts to distribute TEGSEDI (inotersen)subcutaneous injection for the treatment of polyneuropathy of hereditarytransthyretin-mediated (hATTR) amyloidosis in adults. In August 2018, AlnylamPharmaceuticals, Inc. partnered with US Bioservices, a specialty pharmacy andpart of AmerisourceBergen, to dispense ONPATTRO (patisiran) lipid complexinjection.
Transthyretin amyloidosis is arare disease and its symptoms are not easily identified. It is therefore,diagnosed late, which in turn affects the course of action in terms oftreatment. According to the data published by The American Journal of ManagedCare in 2017, hereditary transthyretin-mediated (hATTR) amyloidosis affectsaround 50,000 patients worldwide. However, the diagnosis rate of disease is verylow. According to the study published by Alnylam Pharmaceuticals, Inc., inJanuary 2018, the diagnosis rate of hATTR in the U.S. is around ~10-30%, whichis expected to be a major factor restraining growth of the market over theforecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/transthyretin-amyloidosis-treatment-market-687
Key Takeaways of the GlobalTransthyretin Amyloidosis Treatment Market:
The global transthyretinamyloidosis treatment market is expected to exhibit a CAGR of 4% over theforecast period, owing to product launches by manufacturers such as AlnylamPharmaceuticals, Inc. and Ionis Therapeutics
North America is expected to holddominant position in the global transthyretin amyloidosis treatment market overthe forecast period, owing to approval and launch of new products in theregion. For instance, in June 2017, the U.S. Food and Drug Administration (FDA)granted Fast Track designation to Pfizer Inc.’s Tafamidis, the company’sinvestigational treatment therapy for Transthyretin Cardiomyopathy (TTR-CM).
Asia Pacific is expected towitness significant growth in the market due increasing approvals of noveltherapies in the region. For instance, in March, 2018, the Ministry of HealthLabor and Welfare in Japan granted SAKIGAKE designation to Pfizer Inc.’sTafamidis, for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
However, no approved drugs areavailable for the treatment of cardiomyopathy. Therefore, key players in themarket are could focus on this opportunity to receive approval for their drugsfor cardiomyopathy indication and can launch their drug in key region such asthe U.S. to enhance their market share.
Similar to cardiomyopathy, nospecifically approved drug is available for the treatment of wild-typetransthyretin amyloidosis. Therefore, key players could focus on thisopportunity to develop drugs for the treatment of wild type disease to gainhigh revenue and market share.
Major players operating in theglobal transthyretin amyloidosis treatment market include, AlnylamPharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKlinePlc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM InnovationBiotech, S.L.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/687
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-173
